Ligand Pharmaceuticals Inc (LGND)

105.62
0.79 0.74
NASDAQ : Health Care
Prev Close 106.41
Open 106.48
Day Low/High 105.19 / 108.00
52 Wk Low/High 71.63 / 138.94
Volume 189.13K
Avg Volume 332.10K
Exchange NASDAQ
Shares Outstanding 20.90M
Market Cap 2.22B
P/E Ratio 67.78
Div & Yield N.A. (N.A)

Latest News

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Ligand Pharmaceuticals Incorporated To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Ligand Pharmaceuticals Incorporated To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Ligand Pharmaceuticals Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Ligand Pharmaceuticals Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Ligand Pharmaceuticals Inc.

Ligand Enters Commercial License And Supply Agreements For Captisol®-enabled Trametinib

Ligand Enters Commercial License And Supply Agreements For Captisol®-enabled Trametinib

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into global license and supply agreements with Novartis for the development and commercialization of a Captisol-enabled oral liquid formulation of...

Ligand Enters Into Worldwide OmniAb® Platform License Agreement With ONO PHARMACEUTICAL CO., LTD.

Ligand Enters Into Worldwide OmniAb® Platform License Agreement With ONO PHARMACEUTICAL CO., LTD.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with ONO PHARMACEUTICAL CO.

Lantern Foundation Founder Urges Senate Committee To Commence Investigation Into Ligand Pharmaceuticals

Lantern Foundation Founder Urges Senate Committee To Commence Investigation Into Ligand Pharmaceuticals

Abuse of Orphan Drug Act, Accounting and Ethical Violations Warrant Congressional and Regulatory Investigation, Organization's Founder Says

LGND SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Ligand Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of January 17, 2017

LGND SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Ligand Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of January 17, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Ligand Pharmaceuticals Inc.

LGND NOTICE: Rosen Law Firm Reminds Ligand Pharmaceuticals Incorporated Investors Of Important Deadline In Class Action Filed By Firm - LGND

LGND NOTICE: Rosen Law Firm Reminds Ligand Pharmaceuticals Incorporated Investors Of Important Deadline In Class Action Filed By Firm - LGND

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Ligand Pharmaceuticals Incorporated securities (NASDAQ:LGND) from November 9, 2015 through November 14, 2016, both dates inclusive (the "Class...

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated And Encourages Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated And Encourages Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (Nasdaq: LGND).

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated And Encourages Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (Nasdaq: LGND) concerning possible violations of federal...

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated - LGND

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated - LGND

Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Ligand Pharmaceuticals Incorporated securities (NASDAQ:LGND) from November 9, 2015 through...

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Ligand Pharmaceuticals Incorporated

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Ligand Pharmaceuticals Incorporated

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) resulting from allegations...

SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Ligand Pharmaceuticals Incorporated And Advises Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Ligand Pharmaceuticals Incorporated And Advises Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (Nasdaq: LGND) concerning possible violations of...

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Ligand Pharmaceuticals Incorporated And Advises Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Ligand Pharmaceuticals Incorporated And Advises Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (Nasdaq: LGND) concerning possible violations of federal...

Ligand Reports Third Quarter 2016 Financial Results

Ligand Reports Third Quarter 2016 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2016, and provided an operating forecast and program updates.

Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application For Hospital-Treated Skin Infections

Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application For Hospital-Treated Skin Infections

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that it has submitted New Drug...